Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03719105 | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | recruiting | Early Phase 1 | 40 | New York Medical CollegeOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05838599 | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides | recruiting | Early Phase 1 | 25 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07162012 |
| Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma(Anti-EBV TCR-T) |
| recruiting |
| Early Phase 1 |
| 24 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| Dec 2, 2025 |
| clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06633354 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials